Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 6;7(49):81292-81304.
doi: 10.18632/oncotarget.13223.

The prognostic value of long non coding RNAs in non small cell lung cancer: A meta-analysis

Manni Wang  1 , Xuelei Ma  1 , Chenjing Zhu  1 , Linghong Guo  1 , Qingfang Li  1 , Ming Liu  1 , Jing Zhang  2
Affiliations
Review

The prognostic value of long non coding RNAs in non small cell lung cancer: A meta-analysis

Manni Wang et al. Oncotarget. .

Abstract

Background: Reports have demonstrated the prognostic function of long non-coding RNAS (lncRNAS) in patients with cancer. However, their prognostic functions in non small cell lung cancer (NSCLC) remain controversial. We therefore performed a meta-analysis on six lncRNAs (PVT1, AFAP1-AS1, LINC01133, ANRIL, MEG3 and UCA1) to clarify their prognostic roles in NSCLC.

Results: Thirty-six studies involving 6267 patients with NSCLC and 34 lncRNAs were included. Of the listed lncRNAs, 20 were shown to negatively affect patients' overall survival while the high expression of 13 lncRNAs indicated better survival outcomes.

Materials and methods: The log-rank p value and Kaplan-Meier survival curves of survival outcomes were extracted for hazard ratio (HR) calculation. Survival outcomes were measured by overall survival (OS) and event free survival (EFS) which were then analyzed by calculating pooled hazard ratios. The heterogeneity was detected by Q statistic and I-squared statistic.

Conclusions: The abnormal expression of lncRNAs may significantly affect NSCLC patients' survival and may serve as a novel predictive factor for prognosis of NSCLC patients.

Keywords: NSCLC; lncRNAs; meta-analysis; prognosis.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

None.

Figures

Figure 1
Figure 1. The flow chart of selection process
Figure 2
Figure 2. Forrest plots of studies evaluating hazard ratios of high PVT1 expression as compared to low expression
Figure 3
Figure 3. Forrest plots of studies evaluating hazard ratios of high AFAP1-AS1 expression as compared to low expression with 2 cohorts of one study
Figure 4
Figure 4. Forrest plots of studies evaluating hazard ratios of high AFAP1-AS1 expression as compared to low expression
Figure 5
Figure 5. Forrest plots of studies evaluating hazard ratios of high LINC01133 expression as compared to low expression
Figure 6
Figure 6. Forrest plots of studies evaluating hazard ratios of high ANRIL expression as compared to low expression
Figure 7
Figure 7. Forrest plots of studies evaluating hazard ratios of high UCA1 expression as compared to low expression
Figure 8
Figure 8. Forrest plots of studies evaluating hazard ratios of high MEG3 expression as compared to low expression
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Ramalingam S, Pawlish K, Gadgeel S, Demers R, Kalemkerian GP. Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database. Journal of clinical oncology. 1998;16:651–657. - PubMed
    1. Globocan 2012 IARC. http://globocaniarcfr/Pages/fact_sheets_canceraspx. Accessed July 18, 2014.
    1. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. Journal of thoracic oncology. 2009;4:792–801. - PubMed
    1. van Rens MT, de la Riviere AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest. 2000;117:374–379. - PubMed
    1. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer cell. 2006;9:189–198. - PubMed

MeSH terms